NCT04906473View on ClinicalTrials.gov

Safety,Tolerability, Pharmacokinetic,Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

July 31, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

October 31, 2023

Conditions
Advanced Solid Tumor
Interventions
DRUG

KY100001

KY100001; Tablet; Oral route; Dose escalation and dose extension

Sponsors
All Listed Sponsors
lead

Kunming Pharmaceuticals, Inc.

INDUSTRY